Scholar Rock Holding (SRRK) Non-Current Deffered Revenue (2017 - 2020)
Scholar Rock Holding's (SRRK) quarterly Non-Current Deffered Revenue came in at $33.2 million in Q4 2020, down 28.6% year-on-year from $46.5 million in Q1 2020, and down 14.32% quarter-over-quarter from $38.7 million in Q3 2020.
Scholar Rock Holding (SRRK) Non-Current Deffered Revenue (2017 - 2020) Analysis & Trends
Scholar Rock Holding's Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $33.2 million for Q4 2020.
- On a quarterly basis, Non-Current Deffered Revenue fell 28.6% year-over-year to $33.2 million in Q4 2020; TTM through Dec 2020 was $33.2 million, a 28.6% decrease from a year earlier, with the FY2020 full-year figure at $33.2 million, down 28.6% from the prior year.
- Non-Current Deffered Revenue retreated to $33.2 million in Q4 2020 per SRRK's latest filing, from $38.7 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $46.5 million in Q4 2019 and bottomed at $468000.0 in Q4 2017.
- The 4-year median for Non-Current Deffered Revenue is $33.8 million (2019), against an average of $28.6 million.
- Across the five-year window, Non-Current Deffered Revenue soared 9022.86% in 2018 and slipped 28.6% in 2020, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $468000.0 in 2017, then surged by 9022.86% to $42.7 million in 2018, then gained by 8.89% to $46.5 million in 2019, then declined by 28.6% to $33.2 million in 2020.
- Per Business Quant, the three latest SRRK Non-Current Deffered Revenue figures stand at $33.2 million (Q4 2020), $38.7 million (Q3 2020), and $38.1 million (Q2 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 33.19 Mn |
| Sep 30, 2020 | 38.74 Mn |
| Jun 30, 2020 | 38.12 Mn |
| Mar 31, 2020 | 46.11 Mn |
| Dec 31, 2019 | 46.49 Mn |
| Sep 30, 2019 | 29.73 Mn |
| Jun 30, 2019 | 31.24 Mn |
| Mar 31, 2019 | 34.43 Mn |
| Dec 31, 2018 | 42.70 Mn |
| Sep 30, 2018 | 886,000.00 |
| Jun 30, 2018 | 681,000.00 |
| Dec 31, 2017 | 468,000.00 |